ENTACAPONE COMBI ACTAVIS 50/12.5/200 levodopa/carbidopa/entacapone 50/12.5/200 mg tablet bottle

Pajjiż: Awstralja

Lingwa: Ingliż

Sors: Department of Health (Therapeutic Goods Administration)

Ingredjent attiv:

levodopa, Quantity: 50 mg; carbidopa monohydrate, Quantity: 13.5 mg (Equivalent: carbidopa, Qty 12.5 mg); entacapone, Quantity: 200 mg

Disponibbli minn:

Medis Pharma Pty Ltd

INN (Isem Internazzjonali):

carbidopa monohydrate,Entacapone,Levodopa

Għamla farmaċewtika:

Tablet, film coated

Kompożizzjoni:

Excipient Ingredients: hyprolose; microcrystalline cellulose; powdered cellulose; sodium sulfate; trehalose dihydrate; magnesium stearate; carmellose sodium; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin

Rotta amministrattiva:

Oral

Unitajiet fil-pakkett:

100 tablets

Tip ta 'preskrizzjoni:

(S4) Prescription Only Medicine

Indikazzjonijiet terapewtiċi:

levodopa/carbidopa/entacapone is indicated for the management of patients with Parkinson?s disease who are experiencing motor fluctuations.

Sommarju tal-prodott:

Visual Identification: Red, oval, biconvex coated tablet with '50' on one side and 'LEC'on the other side; Container Type: Bottle; Container Material: HDPE; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

L-istatus ta 'awtorizzazzjoni:

Licence status A

Data ta 'l-awtorizzazzjoni:

2013-10-03